<DOC>
	<DOCNO>NCT00474929</DOCNO>
	<brief_summary>RATIONALE : Sorafenib everolimus may stop growth cancer cell block blood flow cancer block enzyme need cell growth . PURPOSE : This phase I/II trial study side effect best dose sorafenib everolimus see well work treat patient relapsed refractory non-Hodgkin 's lymphoma , Hodgkin 's lymphoma , multiple myeloma .</brief_summary>
	<brief_title>Sorafenib Everolimus Treating Patients With Relapsed Refractory Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) sorafenib tosylate everolimus patient relapse refractory non-Hodgkin 's lymphoma , Hodgkin 's lymphoma , multiple myeloma . - Determine toxicity regimen patient . - Evaluate therapeutic activity regimen patient . - Evaluate pharmacokinetic interaction regimen . - Correlate clinical ( toxicity and/or tumor response activity ) effect pharmacologic ( pharmacokinetic/pharmacodynamic ) parameter and/or biologic ( correlative laboratory ) result . OUTLINE : This multicenter , dose-escalation , phase I study follow phase II study . - Phase I ( close accrual 2/10/2009 ) : Patients receive oral sorafenib tosylate oral everolimus day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sorafenib tosylate everolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience Dose Limiting Toxicity ( DLT ) . - Phase II : Patients receive oral sorafenib tosylate twice daily oral everolimus daily MTD determine phase I . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood bone marrow collect periodically study analyzed flow cytometry , immunohistochemistry , enzyme-linked immunosorbent assay . Patients enrol phase I also undergo blood sample collection day 8 15 course 1 day 1 subsequent course pharmacokinetic study . After completion study treatment , patient follow every 6 month 3 year . PROJECTED ACCRUAL : A total 103 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 following : Multiple myeloma NonHodgkin 's lymphoma Hodgkin 's lymphoma Relapsed refractory disease Measurable disease , define accord diagnosis follow : Multiple myeloma , meet 1 follow criterion : Serum monoclonal protein ≥ 1.0 g/dL Urine monoclonal protein ≥ 200 mg 24hour electrophoresis Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥ 30 % ( evaluable disease ) Lymphoma , meet 1 follow criterion : Measurable disease CT scan MRI PET/CT scan , define ≥ 1 lesion single diameter ≥ 2 cm OR tumor cell blood ≥ 5 x10^9/L Skin lesion use area ≥ 2 cm ≥ 1 diameter photograph ruler Lymphoplasmacytic lymphoma without measurable lymphadenopathy , meet follow criterion : Bone marrow lymphoplasmacytosis &gt; 10 % lymphoplasmacytic cell aggregate , sheet , lymphocyte , plasma cell , lymphoplasmacytic cell bone marrow biopsy Quantitative IgM monoclonal protein &gt; 1,000 mg/dL Not candidate know standard potentially curative therapy PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,500/mm³ Hemoglobin ≥ 9 g/dL Platelet count ≥ 75,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) OR direct bilirubin normal AST ≤ 3 time ULN ( 5 time ULN liver involvement ) Creatinine ≤ 2.5 time ULN INR &lt; 1.5 activated PTT &lt; 1.5 time ULN ( concurrent anticoagulant ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week completion study treatment No uncontrolled infection No NYHA class IIIIV congestive heart failure No unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) No myocardial infarction within past 6 month No uncontrolled hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg , despite optimal medical management No known HIV positivity No active malignancy require treatment No inability swallow No gastrointestinal ( GI ) function impairment GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) preclude use oral medication No thrombolic embolic event ( e.g. , cerebrovascular accident , include transient ischemic attack ) within past 6 month No pulmonary hemorrhage bleed event ≥ grade 3 within past 4 week No severe uncontrolled medical condition condition would preclude study compliance No liver disease , cirrhosis , chronic hepatitis chronic persistent hepatitis , uncontrolled infection No serious nonhealing wound , ulcer , bone fracture No evidence history serious bleed diathesis coagulopathy , hemophilia von Willebrand 's disease No significant traumatic injury within past 4 week No know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) PRIOR CONCURRENT THERAPY : More 3 week since prior myelosuppressive chemotherapy biological therapy recover More 4 week since prior major surgery open biopsy Lymph node biopsy within past 4 week allow Prior everolimus allow No concurrent immunosuppressant therapy Concurrent stable chronic dos steroid ( ≤ 20 mg prednisone per day ) disorder lymphoma ( i.e. , rheumatoid arthritis , polymyalgia rheumatica , adrenal insufficiency , asthma ) pruritus fever associate lymphoma allow Concurrent corticosteroid low possible dose necessary control symptoms patient CNS lymphoma allow No concurrent CYP450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John 's wort ) No concurrent immunotherapy , radiotherapy , chemotherapy No concurrent chronic oxygen therapy No concurrent warfarin heparin No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
</DOC>